The GPR55 antagonist CID16020046 protects against intestinal inflammation.

“G protein-coupled receptor 55 (GPR55) is a lysophospholipid receptor responsive to certain cannabinoids.

The role of GPR55 in inflammatory processes of the gut is largely unknown. Using the recently characterized GPR55 inhibitor CID16020046, we determined the role of GPR55 in experimental intestinal inflammation and explored possible mechanisms of action…

Pharmacological blockade of GPR55 reduces experimental intestinal inflammation by reducing leukocyte migration and activation, in particular that of macrophages. Therefore, CID16020046 represents a possible drug for the treatment of bowel inflammation.”

http://www.ncbi.nlm.nih.gov/pubmed/26227635

Leave a Reply

Your email address will not be published. Required fields are marked *